RAPT Therapeutics (RAPT) Adds to Intra-Day Gains Despite Stock Offering; Last Up 23%

June 14, 2021 5:46 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

RAPT Therapeutics (NASDAQ: RAPT) is adding to its intra-day gains despite announcing a $125 million share stock offering.

Shares are up 22.5% after-hours after gaining 115% intra-day on positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Momentum Movers, Trader Talk